| 7.4953 -0.285 (-3.66%) | 01-30 15:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.21  |
1-year : | 10.76 |
| Resists | First : | 7.88 |
Second : | 9.21 |
| Pivot price | 6.86 |
|||
| Supports | First : | 6.44 |
Second : | 5.55 |
| MAs | MA(5) : | 7.59 |
MA(20) : | 6.64 |
| MA(100) : | 5.97 |
MA(250) : | 6.02 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 89.9 |
D(3) : | 91.4 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 10.67 | Low : | 4.15 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VIR ] has closed below upper band by 28.0%. Bollinger Bands are 133.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.81 - 7.85 | 7.85 - 7.88 |
| Low: | 7.41 - 7.45 | 7.45 - 7.49 |
| Close: | 7.71 - 7.78 | 7.78 - 7.84 |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Fri, 23 Jan 2026
Vir Biotechnology, Inc. (VIR) Stock Analysis: A Biotech with a Promising 131% Upside Potential - DirectorsTalk Interviews
Fri, 23 Jan 2026
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mon, 12 Jan 2026
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones - Business Wire
Wed, 17 Dec 2025
Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Latham & Watkins LLP
Wed, 17 Dec 2025
Norgine gets in on Vir's hepatitis D program with €550M European licensing pact - Fierce Biotech
Wed, 05 Nov 2025
Vir Biotechnology announces completion of enrollment in ECLIPSE 1 Phase 3 trial for chronic hepatitis delta - European AIDS Treatment Group
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 139 (M) |
| Held by Insiders | 9.774e+007 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 11,110 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.1147e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -72 % |
| Return on Assets (ttm) | 267.9 % |
| Return on Equity (ttm) | -26 % |
| Qtrly Rev. Growth | 1.686e+007 % |
| Gross Profit (p.s.) | -64.68 |
| Sales Per Share | -35.3 |
| EBITDA (p.s.) | -3.07899e+008 |
| Qtrly Earnings Growth | -3.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -454 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.22 |
| Price to Cash Flow | 1.81 |
| Dividend | 0 |
| Forward Dividend | 1.175e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |